FDA warns Chinese manufacturer for lack of vision when making sterile eye drops

When it comes to making eye drops, one Chinese manufacturer failed to clearly see the rules for sterile manufacturing, according to the U.S. Food and Drug Administration.

Hubei Kangzheng was admonished by the regulator for a host of production lapses that could have led to microbial contamination in its Pi Yen Chin drops, according to a Nov. 23, 2021, warning letter that was posted on the agency web site this week.

A key issue was that the company also made non-sterile nasal drops and wrongfully believed its manufacturing standards did not need to comply with procedures for sterile ophthalmic drops, which are sold over-the-counter. The FDA referred to this argument as a “misguided notion.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In